VIVLODEX Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Vivlodex, and what generic alternatives are available?
Vivlodex is a drug marketed by Iceutica Operations and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has seventeen patent family members in seventeen countries.
The generic ingredient in VIVLODEX is meloxicam. There are twenty-two drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the meloxicam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vivlodex
A generic version of VIVLODEX was approved as meloxicam by AVONDALE PHARMS on June 1st, 2004.
Summary for VIVLODEX
International Patents: | 17 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 143 |
Patent Applications: | 674 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VIVLODEX |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIVLODEX |
What excipients (inactive ingredients) are in VIVLODEX? | VIVLODEX excipients list |
DailyMed Link: | VIVLODEX at DailyMed |



Anatomical Therapeutic Chemical (ATC) Classes for VIVLODEX
US Patents and Regulatory Information for VIVLODEX
VIVLODEX is protected by four US patents.
Patents protecting VIVLODEX
Formulation of meloxicam
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Formulation of meloxicam
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Formulation of meloxicam
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM
Formulation of meloxicam
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Iceutica Operations | VIVLODEX | meloxicam | CAPSULE;ORAL | 207233-001 | Oct 22, 2015 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Iceutica Operations | VIVLODEX | meloxicam | CAPSULE;ORAL | 207233-002 | Oct 22, 2015 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Iceutica Operations | VIVLODEX | meloxicam | CAPSULE;ORAL | 207233-001 | Oct 22, 2015 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for VIVLODEX
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Norbrook Laboratories (Ireland) Limited | Loxicom | meloxicam | EMEA/V/C/000141 DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsAlleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic. |
Authorised | yes | no | no | 2009-02-10 | |
Le Vet Beheer B.V. | Novaquin | meloxicam | EMEA/V/C/003866 Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses. |
Authorised | no | no | no | 2015-09-08 | |
Le Vet Beheer B.V | Meloxidolor | meloxicam | EMEA/V/C/002590 DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsReduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic. |
Authorised | yes | no | no | 2013-04-22 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for VIVLODEX
See the table below for patents covering VIVLODEX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20170017915 | 멜록시캄의 신규 제형 (A NOVEL FORMULATION OF MELOXICAM) | See Plans and Pricing |
Japan | 2017517551 | メロキシカムの新規製剤 | See Plans and Pricing |
Morocco | 39443 | Nouvelle formulation de méloxicam | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |